Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Trial Profile

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Linagliptin (Primary) ; CD26 antigen inhibitors; Sulfonylureas; Thiazolidinediones
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 30 Dec 2017 to 31 May 2018.
    • 28 Nov 2017 Planned primary completion date changed from 30 Dec 2017 to 31 May 2018.
    • 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top